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Abstracts
 
BACKGROUND:
 
 Selection of biological versus mechani-
cal heart valve replacement entails tradeoffs in the risk and
expected cost of post-operative bleeding, embolic events
and reoperation. Additionally, the risk of these events var-
ies by age at implant.
OBJECTIVE: To identify the direct medical costs to the
NHS of biological and mechanical valve replacement in
younger versus older patients.
METHODS: A Markov decision-analytic model was con-
structed to identify the cumulative lifetime costs of valve
replacement and related events in a simulated cohort of
10,000 patients followed from valve implantation until
death. Events included bleeding, embolism, endocarditis,
structural valve deterioration, reoperation and death. Event
rates were modeled using linear, and non-linear statistical
hazard functions based on clinical series reported in the
literature. Medical resource use related to events was es-
timated based on clinical expert opinion. Costs were as-
signed to each event using standard lists of NHS costs.
RESULTS: For aortic valve replacement, the expected life-
time costs were £6,812 (biological) and £8,873 (mechani-
cal) for persons aged 60, versus £6,281 (biological) and
£8,137 (mechanical) for persons aged 70 at implant, re-
spectively. In the mitral position, costs were £6,968 (biolog-
ical) and £8,760 (mechanical) versus £6,299 (biological)
and £7,989 (mechanical) in persons aged 60 versus 70 at
implant respectively. Results were most sensitive to bleed-
ing, embolic and reoperation event rates, but less sensitive
to the cost per event.
CONCLUSION: The expected lifetime cost of biologic
valve replacement was lower than mechanical valve re-
placement for both age groups and valve positions. This
suggests the economic impact of anticoagulation therapy,
bleeding and embolic events, which occur at higher rates in
the mechanical valve, is greater than the economic impact
of structural valve deterioration leading to reoperation,
which is greater in the biological valve.
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BACKGROUND: Economic analyses of cardiovascular dis-
ease (CVD) prevention with statins have generated contro-
versy on the most efficient allocation of health care funds:
primary prevention, secondary or both? Previous analyses
have focused on one setting or the other. Comparing these
two oversimplifies the task of allocating health care re-
sources and may lead to unjustified decisions concerning
“appropriate” statin use. Instead, an integrated view across
the continuum of risk is required.
METHODS: An economic model of CVD prevention with
pravastatin—Continuum of Risk Evaluation (CORE)—
based on West of Scotland Coronary Prevention Study (pri-
mary prevention) and Cholesterol and Recurrent Events
(secondary prevention) study data is detailed. The model
simulates 10,000 individuals at various stages of CVD
(prior manifestation of CVD through multiple events). All
events are tallied in monthly cycles with costs and life ex-
pectancy implications applied appropriately.
ANALYSES: Analyses were completed for various popula-
tions and treatment strategies to help determine the most
cost-effective scenarios. For the purpose of these analyses,
populations were described in terms of the proportion of
individuals at various disease stages at the start of follow-
up. Treatment strategies were defined on the basis of the
risk cut-off at which treatment is initiated for individuals
without pre-existing disease. Analyses were conducted fol-
lowing the NCEP and Canadian treatment guidelines.
CONCLUSION: An integrated approach to prevention of
CVD is an area that has not been explored in term of its
economic impact. CORE permits realistic analysis of pol-
icy decisions which involve the entire continuum of risk
rather then isolated consideration of specific, but arbi-
trary, “stages” of disease.
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OBJECTIVE: To examine whether amlodipine can reduce
hospitalization associated with treatment of cardiovascu-
lar disease (CVD) in patients with angiographic evidence
of coronary artery disease. Amlodipine is a long acting cal-
cium channel antagonist that has been proven to be effec-
tive in treating cardiovascular diseases.
METHOD: We used clinical data derived from the Pro-
spective Randomized Evaluation of Vascular Effects of
Norvasc Trial (PREVENT). PREVENT was a 3-year, ran-
domized, masked, placebo-controlled, multicenter, clinical
trial originally designed to test the antiatherogenic effect of
the calcium channel blocker amlodipine in 825 patients
with coronary artery disease (417 patients for amlodipine
and 408 patients for placebo). The outcome measures were
clinical CVD events associated with hospital care which in-
cluded congestive heart failure (CHF), myocardial infarc-
tion (MI), stroke, angina, coronary artery bypass graft
(CABG), percutaneous coronary angioplasty (PTCA), stents,
athrectomy, valve replacement, and catheterization.
RESULTS: Overall, the net number of hospitalization asso-
ciated with CVD averted was 27.9 per 100 patients
(38.51% reduction) in the amlodipine patient group over
three years of the study. Comparing with the placebo group,
the treatment group had fewer hospitalizations related to
PTCA (11.75 per 100 patients, 52.69% reduction),
CABG (3.03, 42.62% reduction), stent (2.02, 41.22%
reduction), angina (9.27, 31.52% reduction), and CHF
